Other OTC - Other OTC Delayed Price. Currency in USD
0.040.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.04
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Bayer AG :BAYN-DE: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
    Capital Cube27 days ago

    Bayer AG :BAYN-DE: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016

    Categories: Yahoo Finance Click here to see latest analysis Bayer AG reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Bayer AG – Novartis AG, Eli Lilly and Company, Roche Holding AG, Merck & Co., Inc. and GlaxoSmithKline plc (NOVN-CH, LLY-CH, RO-CH, MRK-FR and GSK-GB) that have ... Read more (Read more...)

  • MarketWatch2 months ago

    Monsanto misses profit and sales expectations; shares drop

    Monsanto Co. reported fiscal third-quarter earnings that declined to $717 million, or $1.63 a share, from $1.14 billion, or $2.39 a share, in the same period a year ago. Excluding non-recurring items, ...

  • TheStreet.com2 months ago

    Sanofi's Likely Sweetener for Medivation Panned

    The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.